Granules India subsidiary completes US FDA inspection with five procedural observations

Business Updates View source PDF Explain this filing

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹583.30

prior close

₹585.10

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%+1.7% vs market

Pharmaceuticals peers, median of 155sector+0.7%+2.0% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Smallcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.4

15m

-0.1

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7+1.0+1.7+0.7+2.0

Next day

+5.6+1.4+4.2+0.6+5.0

+5.0+1.4+3.6+0.6+4.4

+5.5+1.3+4.2+0.0+5.5

+3.3+0.7+2.6-0.7+4.0

+2.5+0.5+2.0-0.8+3.3

+6.3+1.6+4.7-0.0+6.3

15d

+1.0-1.2+2.2-2.1+3.2

-1.9-4.8+2.9-6.2+4.3

+2.5-2.3+4.8-5.6+8.1

+0.6-13.3+13.8-13.7+14.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wholly owned subsidiary Granules Life Sciences Private Limited, based in Hyderabad, completed a US FDA GMP and Prior Approval Inspection from December 15 to 19, 2025. The inspection concluded with five observations related to procedural requirements. None of the observations involve data integrity or product safety. The company will submit its response to the FDA within the stipulated timeframe. The facility manufactures Pharma Formulation Intermediates and Finished Dosages.

Likely market impact

Five observations are procedural only, not data or safety related. Manageable but may cause short term uncertainty on approvals from this facility.